<?xml version="1.0" encoding="UTF-8"?>
<p>Data for budesonide and beclomethasone, locally acting corticosteroids with low systemic bioavailability, demonstrate that these medications are associated with significantly fewer side effects when compared to systemic corticosteroids with adverse events similar to placebo.
 <xref rid="apt15779-bib-0065" ref-type="ref">
  <sup>65</sup>
 </xref>, 
 <xref rid="apt15779-bib-0066" ref-type="ref">
  <sup>66</sup>
 </xref>, 
 <xref rid="apt15779-bib-0067" ref-type="ref">
  <sup>67</sup>
 </xref>, 
 <xref rid="apt15779-bib-0068" ref-type="ref">
  <sup>68</sup>
 </xref>, 
 <xref rid="apt15779-bib-0069" ref-type="ref">
  <sup>69</sup>
 </xref>
 <boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0002" orientation="portrait">
  <p>
   <bold>Corticosteroids</bold>
   <list list-type="bullet" id="apt15779-list-0002">
    <list-item>
     <p>Corticosteroids (particularly ≥20 mg prednisolone or its equivalent) are associated with an increased risk of infection; however, it is unclear if treatment with corticosteroids is associated with an increased risk of COVID‐19 infection or complications.</p>
    </list-item>
    <list-item>
     <p>Where possible, corticosteroid use should be avoided and rapid tapering should be considered ± switch to budesonide. This must be weighed up against the risk of IBD flare.</p>
    </list-item>
    <list-item>
     <p>If a patient requires a course of corticosteroids to treat a flare, consider the use of budesonide or beclomethasone where possible, and in CD, consider exclusive enteral nutrition (EEN) as an alternative induction agent.</p>
    </list-item>
    <list-item>
     <p>If a patient is in contact with a person with COVID‐19 or develops COVID‐19, taper corticosteroids ± switch to budesonide or beclomethasone where possible, but consider need for stress‐dose steroids if septic or shocked.</p>
    </list-item>
   </list>
  </p>
 </boxed-text>
</p>
